Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: A Focus paper by the epidemiology committee of ECCO

Journal of Crohn's and Colitis

Volumn 10, Issue 2, 2016, Pages 216-225

  Annese, Vito ^a   Duricova, Dana ^b   Gower Rousseau, Corinne ^c   Jess, Tine ^d   Langholz, Ebbe ^e  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIV LILLE   (France)

^d STATENS SERUM INSTITUT   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anti Tumour necrosis factor; Cancer; Crohn s disease; Hospitalisation; Immunosuppressant therapy; Infections; Mortality; Surgery; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PREDNISONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

BIOLOGICAL THERAPY; CANCER RISK; CELIAC DISEASE; COLECTOMY; CROHN DISEASE; HAZARD RATIO; HOSPITALIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATORY BOWEL DISEASE; LENGTH OF STAY; LYMPHOMA; MALIGNANT NEOPLASM; MORTALITY; MORTALITY RATE; NON MELANOMA SKIN CANCER; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ULCERATIVE COLITIS; UTERINE CERVIX CANCER; ABDOMINAL SURGERY; COMPLICATION; HEALTH; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASES; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TRENDS;

DIGESTIVE SYSTEM SURGICAL PROCEDURES; GLOBAL HEALTH; HOSPITALIZATION; HUMANS; INCIDENCE; INFECTION; INFLAMMATORY BOWEL DISEASES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 85012179675     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv190     Document Type: Review

References (105)

1. Danese S, Vuitton L, Peyrin-Biroulet L. Biological agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 2015;12:537 45.
2. Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B. Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease [IOIBD]. Hospitalisations and surgery in Crohn s disease. Gut 2012;61:622 9.
3. van der Valk ME, Mangen MJ, Leenders M, et al. COIN study group and the Dutch Initiative on Crohn and Colitis. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014;63:72 9.
4. Samuel S, Ingle SB, Dhillon S, , et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 2013;19:1858 66.
5. Nguyen GC, Nugent Z, Shaw S, Bernstein CN. Outcomes of patients with Crohn s disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011;141:90 7.
6. Vester-Andersen MK, Vind I, Prosberg MV, et al. Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003 2011 a Danish population-based cohort study. J Crohns Colitis 2014;8:1675 83.
7. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2007 5:597 601.
8. Herrinton LJ, Liu L, Fireman B, et al. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998 2005. Gastroenterology 2009;137:502 11.
9. Pant C, Anderson MP, Deshpande A, et al. Trends in hospitalizations of children with inflammatory bowel disease within the United States from 2000 to 2009. J Investig Med 2013;61:1036 8.
10. Sandberg KC, Davis MM, Gebremariam A, Adler J. Increasing hospitalizations in inflammatory bowel disease among children in the United States, 1988 2011. Inflamm Bowel Dis 2014;20:1754 6.
11. Jakubowski A, Zagorowicz E, Kraszewska E, Bartnik W. Rising hospitalization rates for inflammatory bowel disease in Poland. Pol Arch Med Wewn 2014;124:180 90.
12. Meregaglia M, Banks H, Fattore G. Hospital burden and gastrointestinal surgery in inflammatory bowel disease patients in Italy: A retrospective observational study. J Crohns Colitis 2015;9:853 62.
13. Costa J, Magro F, Caldeira D, Alarcao J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: A systematic review and meta-Analysis. Inflamm Bowel Dis 2013;19:2098 110.
14. Targan SR, Hanauer SB, van Deventer SJ et al. A short-Term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn s disease. Crohn s Disease cA2 Study Group. N Engl J Med 1997;337:1029 35.
15. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infliximab for Crohn s disease: The ACCENT I randomized trial. Lancet 2002;359:1541 9.
16. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn s disease. Gastroenterology 2004;126:402 13.
17. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn s disease. N Engl J Med 2004;350:876 85.
18. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn s disease. Gastroenterology 2005;128:862 9.
19. Gustavsson A, Jarnerot G, Hertervig E, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010;32:984 9.
20. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462 76.
21. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250 60.
22. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn s disease: The CHARM trial. Gastroenterology 2007;132:52 65.
23. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn s disease. Aliment Pharmacol Ther 2010;31:1296 309.
24. Kamm MA, Hanauer SB, Panaccione R, et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn s disease. Aliment Pharmacol Ther 2011;34:306 17.
25. Rutgeerts P1, Van Assche G, Sandborn WJ, et al. EXTEND Investigators. Adalimumab induces and maintains mucosal healing in patients with Crohn s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102 11.
26. Feagan BG, Sandborn WJ, Lazar A, et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014;146:110 8.
27. Schnitzler F, Fidder H, Ferrante M, et al. Long-Term outcome of treatment with infliximab in 614 patients with Crohn s disease: results from a single centre cohort. Gut 2009;58:492 500.
28. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn s disease patients. Adv Ther 2009;26:936 46.
29. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010;105:2617 25.
30. Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn s disease following the introduction of infliximab: A single-centre UK experience. Aliment Pharmacol Ther 2010;32:1357 63.
31. Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T. Hospitalization and surgical rates in patients with Crohn s disease treated with infliximab: A matched analysis. Pharmacoepidemiol Drug Saf 2011;20:838 48.
32. Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn s disease-related healthcare utilization and inpatient costs. Adv Ther 2011;28:671 83.
33. Loomes DE, Teshima C, Jacobs P, Fedorak RN. Health care resource use and costs in Crohn s disease before and after infliximab therapy. Can J Gastroenterol 2011;25:497 502.
34. Waters HC, Vanderpoel JE, Nejadnik B, et al. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. J Med Econ 2012;15:45 52.
35. Abraham NS, Richardson P, Castillo D, Kane SV. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:1281 7.
36. Park KT, Sin A, Wu M, Bass D, Bhattacharya J. Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: A single-center experience. Inflamm Bowel Dis 2014;20:1242 9.
37. Mandel MD, Balint A, Golovics PA, et al. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres. Dig Liver Dis 2014;46:985 90.
38. Vegh Z, Burisch J, Pedersen N, et al. Treatment steps, surgery and hospitalization rates during the first year of follow-up in patients with inflammatory bowel diseases from the 2011 ECCO-EpiCom inception cohort. J Crohns Colitis 2015;9:747 53.
39. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444 51.
40. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn s disease. Gastroenterology 1993;105:1716 23.
41. Jakobsen C, Paerregaard A, Munkholm P, et al. Pediatric inflammatory bowel disease: increasing incidence, decreasing surgery rate, and compromised nutritional status: A prospective population-based cohort study 2007 2009. Inflamm Bowel Dis 2011;17:2541 50.
42. Vind I, Riis L, Jess T, et al.; DCCD study group. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003 2005: A population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006;101:1274 82.
43. Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: A population-based, 7-year follow-up study in the era of immunomodulating therapy Am J Gastroenterol 2014;109:705 14.
44. Pola S, Patel D, Ramamoorthy S, et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:1315 25.
45. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebocontrolled study. Gastroenterology 2005;128:1805 11.
46. Colombel JF, Rutgeerts P, Reinisch W. Early mucosal healing with infliximab is associated with improved long-Term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194 201.
47. Manser CN, Frei P, Grandinetti T, et al.; Investigators of the Swiss IBD Cohort Study. Risk factors for repetitive ileocolic resection in patients with Crohn s disease: results of an observational cohort study. Inflamm Bowel Dis 2014;20:1548 54.
48. Kariyawasam VC, Selinger CP, Katelaris PH, et al. Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn s disease. Inflamm Bowel Dis 2014;20:1382 90.
49. Abraham NS, Richardson P, Castillo D, Kane SV. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:1281 7.
50. Sjoberg D, Holmstrom T, Larsson M, et al. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005 2009-results from the IBD cohort of the Uppsala Region [ICURE]. J Crohns Colitis 2013;7:351 7.
51. Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol 2012;107:1228 35.
52. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: A nationwide cohort study 1979 2011. Gut 2014;63:1607 16.
53. Nyboe Andersen N, Pasternak B, Friis-Moller N, Andersson M, Jess T. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 2015;350:h2809.
54. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409 22.
55. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929 36.
56. Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol 2013;48:595 600.
57. Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biological ThERapy [SABER] study. Ann Rheum. Dis 2014;73:1942 8.
58. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331 9.
59. Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-Tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887 95.
60. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009;30:253 64.
61. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-Tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011;9:30 5.
62. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-Tumor necrosis factor-α therapy in inflammatory bowel disease: meta-Analysis of randomized controlled trials. Am J Gastroenterol 2013;108:1268 76.
63. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn s disease: meta-Analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644 53.
64. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1051 63.
65. Wang X, Zhou F, Zhao J, et al. Elevated risk of opportunistic viral infection in patients with Crohn s disease during biological therapies: A meta analysis of randomized controlled trials. Eur J Clin Pharmacol 2013;69:1891 9.
66. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn s disease. Inflamm Bowel Dis 2009;15:1308 19.
67. Lin Z, Bai Y, Zheng P. Meta-Analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn s disease. Eur J Gastroenterol Hepatol 2011;23:1100 10.
68. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBDsubgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210 26.
69. Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-Tumor necrosis factor therapy in Crohn s Disease. Clin Gastroenterol Hepatol 2015;13:1293-301.
70. Crohn BB, Rosenberg H. The sigmoidoscopic picture of chronic ulcerativecolitis [non-specific]. Am J Med Sci 1925;170:220 8.
71. Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn s disease. Gastroenterology 2013;145:1464 7.
72. Harwood CA, Attard NR, O Donovan P et al. PTCH mutations in basal cell carcinomas from azathioprine-Treated organ transplant recipients. Br J Cancer 2008;99:1276 84.
73. Munz C, Moormann A. Immune escape by Epstein-Barr virus associated malignancies. Semin Cancer Biol 2008;18:381 7.
74. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715 27.
75. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014;63:1416 23.
76. Pasternak B, Svanstrom H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013;177:1296 305.
77. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-Analysis. Clin Gastroenterol Hepatol 2015;13:847 58.
78. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010;8:268 74.
79. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390 9.
80. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621 8.
81. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol 2011;9:449 50.
82. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: A meta-Analysis. Am J Gastroenterol 2014;109:163 9.
83. Allegretti JR, Barnes EL, Cameron A. Are Patients with Inflammatory Bowel Disease on Chronic Immunosuppressive Therapy at Increased Risk of Cervical High-grade Dysplasia/Cancer? A Meta-Analysis. Inflamm Bowel Dis 2015;21:1089 97.
84. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631 6.
85. Rahier JF, Magro F, Abreu C, et al. Second European Evidence-based Consensus on the prevention, diagnosis, and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443 68.
86. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients. A Systematic Review. Drugs 2007;67:1167 98.
87. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet 2009;374:1617 25.
88. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: A UK population-based case-control study. Am J Gastroenterol 2010;105:1604 9.
89. Annese V, Beaugerie L, Egan L, et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis 2015, Aug 20. pii: jjv 141. [Epub ahead of print.]
90. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-Analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275 85.
91. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137 46.
92. Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologicals: A Quebec Claims Database Study. Inflamm Bowel Dis 2015;21:1847 53.
93. Nyboe AN, Pasternak B, Basit S, et al. Association between tumor necrosis factor-Alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014;311:2406 13.
94. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-Analysis: malignancies with anti-Tumour necrosis factor-Alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:447 58.
95. Jess T, Loftus EV Jr, Harmsen WS. Survival and cause specific mortality in patients with inflammatory bowel disease: A long term outcome study in Olmsted County, Minnesota, 1940 2004. Inflamm Bowel Dis 2006;55:1248 54.
96. Hoie O, Schouten LJ, Wolters FL. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut 2007;56:497 503.
97. Huftless SM, Weng X, Liu L. Mortality by medication use among patients with inflammatory bowel disease, 1996 2003. Gastroenterology 2007;133:1779 86.
98. Caspersen S, Elkjaer M, Riis L. Infliximab for inflammatory bowel disease in Denmark 1999 2005: Clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008;6:1212 7.
99. Camus M, Seksisk P, Bourrier A. Long-Term outcome of patients with Crohńs disease who respond to azathioprine. Clin Gastroenterol Hepatol 2013;11:389 94.
100. Lewis JD, Gelfand JM, Troxel AB. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1428 35.
101. Serious infections and mortality in association with therapies for Crohńs disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621 30.
102. Burmester GR, Panaccione R, Gordon KB. Adalimumab: long-Term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohńs disease. Ann Rheum Dis 2013;72:517 24.
103. Herrinton LJ, Liu L, Chen L. Association between anti-TNF-A therapy and all-cause mortality. Pharmacoepidemiol Drug Saf 2012;21:1311 20.
104. Fidder H, Schnitzler F, Ferrante M. Long-Term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study. Gut 2009;58:501 8.
105. De Ridder L, Turner D, Wilson DC. Malignancy and mortality in pediatric patients with inflammatory bowel disease: A multinational study from the Porto Pediatric IBD group. Inflamm Bowel Dis 2014;20:291 300.